DEF 14C: Impact BioMedical Plans Reverse Stock Split

Impact BioMedical Inc. announces a planned reverse stock split with a ratio between 1-for-12.48 and 1-for-50, approved by majority stockholders to enhance market perception and meet listing requirements.

Summary

• The Board of Directors and majority stockholders of Impact BioMedical Inc. have approved a reverse stock split of the company's common stock.
• The reverse stock split ratio will be between 1-for-12.48 and 1-for-50, with the exact ratio to be determined by the Chief Executive Officer.
• The Board has discretionary authority to effect the split at any time on or before December 30, 2026, without further stockholder approval.
• The primary reasons for the reverse stock split include meeting NYSE American continuing listing requirements, improving the stock's trading price, attracting institutional and other investors, and facilitating future equity financings.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive one whole share of common stock.
• The reverse stock split will not change the par value of the common stock ($0.001 per share) or the total number of authorized shares (4,000,000,000 common, 100,000,000 Series A Preferred).

Sentiment

Score: 6

Explanation: The filing describes a strategic corporate action (reverse stock split) aimed at improving market perception and meeting listing requirements, which are generally positive strategic goals. However, it also explicitly outlines several risks and uncertainties associated with the action, preventing a strongly positive sentiment.

Positives

• The reverse stock split is intended to increase the per-share market price of common stock, potentially making it more attractive to institutional investors.
• It aims to help the company meet the continuing listing requirements of the New York Stock Exchange American.
• A higher stock price could improve the company's ability to attract new investors and conduct equity financings on more attractive terms.
• The action is designed to reduce the number of outstanding shares to a level more consistent with other public companies of comparable market capitalizations.
• Reported per share net income or loss will be higher due to fewer outstanding shares.

Negatives

• There is no assurance that the reverse stock split will increase the market price of common stock by a multiple equal to the exchange number or result in a permanent price increase.
• Should the market price decline, the percentage decline as an absolute number and as a percentage of overall market capitalization may be greater than without a reverse stock split.
• Potential liquidity in the market price of common stock could be adversely affected by the reduced number of outstanding shares.
• The reverse stock split will increase the number of stockholders owning 'odd lots' (less than 100 shares), who typically experience higher selling costs and greater difficulty in effecting sales.
• The total market capitalization of common stock after the reverse stock split may be lower than before the split.

Risks

• No assurance that the reverse stock split will achieve the desired increase in stock price or sustained market value.
• Potential for reduced liquidity in the trading market due to fewer outstanding shares.
• Increased costs and difficulty for stockholders holding odd lots (less than 100 shares) to sell their shares.
• The increase in unissued authorized shares could have an anti-takeover effect, potentially discouraging unsolicited takeover attempts and limiting opportunities for stockholders to dispose of shares at higher prices.
• Issuance of additional shares for future financings or acquisitions could have a dilutive effect on earnings per share, book/market value, and stockholder voting power.
• Uncertainty regarding U.S. federal income tax consequences for U.S. Holders, particularly concerning fractional shares being rounded up.

Future Outlook

The Board believes that the reverse stock split is necessary and prudent to reduce the number of outstanding shares to a level more consistent with other public companies of comparable market capitalizations, thereby improving market perception, attracting new investors, and facilitating future equity financings. The CEO has discretionary authority to determine the exact ratio and timing of the split on or before December 30, 2026.

Management Comments

• The Board believes that the number of outstanding shares and low trading price have contributed to a lack of interest from institutional and other investors.
• The Board believes it has been difficult for the Company to attract new investors and conduct equity financings on attractive terms.
• The Board believes that authorizing the Board to effect the Reverse Stock Split is in the Company's and our stockholders' best interests.
• The Board reserves the right not to file the Certificate Amendment and to abandon any Reverse Stock Split without further action by our stockholders at any time before the effectiveness of the filing.

Industry Context

Reverse stock splits are a common corporate action, particularly for companies with low stock prices, often undertaken to meet stock exchange listing requirements (such as minimum bid price) or to make the stock more appealing to a broader range of investors, including institutional funds that may have policies against investing in 'penny stocks.' This action by Impact BioMedical Inc. aligns with these typical motivations, aiming to improve its market standing and facilitate future capital-raising efforts.

Comparison to Industry Standards

• The filing states the aim is to reduce outstanding shares to a level 'more consistent with other public companies with comparable market capitalizations,' but does not provide specific comparable companies, projects, or results for assessment.

Corporate Governance

Related Party Transactions

• DSS, Inc., a majority stockholder owning 88.8% of total votes (92,980,843 shares directly and indirectly), voted in favor of the Corporate Action. This is an approval of a corporate action, not a transaction.

Stakeholder Impact

• Shareholders: Will see their number of shares decrease and the per-share price increase (expected), but face risks of reduced liquidity and potential for greater percentage declines. Those with odd lots may incur higher selling costs.
• Management/Board: Gains discretionary authority to implement the reverse stock split, potentially strengthening their position against unsolicited takeover attempts due to increased unissued authorized shares.
• Potential Investors: The higher stock price and improved marketability aim to attract institutional and other investors, potentially broadening the company's investor base.
• NYSE American: The action is intended to help the company meet listing requirements, maintaining its presence on the exchange.

Next Steps

• The Corporate Action will become effective no sooner than 20 calendar days after the Definitive Information Statement is mailed to stockholders.
• The Chief Executive Officer will determine the exact timing and ratio of the reverse stock split, filing a Certificate of Amendment with the Nevada Secretary of State on or before December 30, 2026.
• Stockholders holding certificated shares will receive a transmittal letter from the transfer agent with instructions to surrender old certificates for book-entry statements of post-split shares.
• Holders of uncertificated shares (book-entry or street name) will have their holdings electronically adjusted by the transfer agent or their brokers/banks.

Key Dates

Keywords

Reverse Stock Split, SEC Filing, Corporate Governance, NYSE American, Listing Requirements, Stockholders, Capitalization, Equity Financing, BioMedical